Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects
/in Dendritic Cells, International Publications, Multiple MyelomaNewcastle disease virus (NDV): brief history of its oncolytic strains
/in International Publications, Newcastle Disease VirusDendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaSelenium and immunocompetence in patients with head and neck cancer
/in International Publications, MicronutrientsTemperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment
/in Hyperthermia, International Publications, Soft Tissue SarcomaGeneration of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaTumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia
/in Hyperthermia, International Publications, Malignant LymphomaInduction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer